VALENCIA, Calif.--(BUSINESS WIRE)--
MannKind Corporation (MNKD) today reported financial results for the first quarter ended March 31, 2013.
For the first quarter of 2013, total operating expenses were $36.4 million, compared to $33.9 million for the first quarter of 2012, an increase of $2.5 million. Research and development (R&D) expenses were $26.4 million for the first quarter of 2013, compared to $24.2 million for the same quarter in 2012, an increase of $2.2 million. This 9% increase was primarily due to an increase in clinical trial related expenses, partially offset by a decrease in facilities related costs and depreciation. General and administrative (G&A) expenses increased by $0.2 million to $10.0 million for the first quarter of 2013, compared to $9.8 million in the first quarter of 2012. This 2% increase in G&A expense was primarily due to an increase in non-cash stock-based compensation expense related to employee stock awards granted during the first quarter of 2013, partially offset by a decrease in legal expenses.
The net loss applicable to common stockholders for the first quarter of 2013 was $41.0 million, or $0.15 per share based on 280.1 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $38.2 million, or $0.27 per share based on 143.2 million weighted average shares outstanding for the first quarter of 2012. The number of common shares outstanding at March 31, 2013 was 289.4 million.
Cash and cash equivalents were $28.0 million at March 31, 2013 and $61.8 million at December 31, 2012 with $125.4 million remaining available for future borrowings under the loan agreement with The Mann Group as of March 31, 2013.
MannKind management will host a conference call to discuss these results today at 5:00 p.m. Eastern Time. To participate in the call please dial (866) 314-9013 or (617) 213-8053 and use the participant passcode: MANNKIND. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 286-8010 or (617) 801-6888 and use the participant passcode: 19493198.
Presenting from the Company will be:
- Chairman and Chief Executive Officer Alfred Mann
- President and Chief Operating Officer Hakan Edstrom
- Corporate Vice President and Chief Financial Officer Matthew Pfeffer
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three months ended
1991 (date of
|Research and development||26,398||24,156||1,493,971|
|General and administrative||10,039||9,777||435,743|
|In-process research and development costs||—||
|Total operating expenses||36,437||33,933||2,100,868|
|Loss from operations||(36,437||)||(33,933||)||(2,097,702||)|
|Other income (expense)||23||1,382||(2,244||)|
|Interest expense on note payable to related party||(1,689||)||(3,048||)||(40,514||)|
|Interest expense on senior convertible notes||(2,863||)||(2,575||)||(42,796||)|
|Loss before benefit for income taxes||(40,965||)||(38,173||)||(2,146,259||)|
|Income tax benefit||—||—||(382||)|
|Deemed dividend related to beneficial conversion feature of convertible preferred stock||—||—||(22,260||)|
|Accretion on redeemable preferred stock||—||—||(952||)|
|Net loss applicable to common stockholders||$||(40,965||)||$||(38,173||)||$||(2,169,089||)|
|Net loss per share applicable to common stockholders — basic and diluted||$||(0.15||)||$||(0.27||)|
|Shares used to compute basic and diluted net loss per share applicable to common stockholders||280,058||143,154|
(A Development Stage Company)
Condensed Consolidated Balance Sheet
March 31, 2013
December 31, 2012
|Cash and cash equivalents||$||28,005||$||61,840|
|Prepaid expenses and other current assets||4,280||4,970|
|Total current assets||32,285||66,810|
|Property and equipment — net||182,290||183,961|
Liabilities and Stockholders’ Deficit
|Senior convertible notes||97,791||97,583|
|Note payable to related party||—||119,635|
Matthew J. Pfeffer
Chief Financial Officer